| Primary |
| Epilepsy |
38.5% |
| Convulsion |
17.5% |
| Product Used For Unknown Indication |
7.3% |
| Partial Seizures |
6.3% |
| Trigeminal Neuralgia |
4.2% |
| Hypertension |
3.1% |
| Bipolar Disorder |
3.0% |
| Affective Disorder |
2.8% |
| Complex Partial Seizures |
2.1% |
| Depression |
2.1% |
| Bipolar I Disorder |
2.0% |
| Status Epilepticus |
1.8% |
| Grand Mal Convulsion |
1.7% |
| Drug Use For Unknown Indication |
1.3% |
| Mania |
1.3% |
| Schizoaffective Disorder |
1.3% |
| Alcohol Withdrawal Syndrome |
1.1% |
| Mental Disorder |
1.0% |
| Pain |
1.0% |
| Acne |
0.8% |
|
| Convulsion |
20.3% |
| Product Substitution Issue |
16.4% |
| Therapeutic Response Unexpected With Drug Substitution |
8.4% |
| Vomiting |
7.7% |
| Hyponatraemia |
5.7% |
| Completed Suicide |
4.2% |
| Rash |
4.2% |
| Drug Exposure During Pregnancy |
3.7% |
| Pharmaceutical Product Complaint |
3.7% |
| Sudden Unexplained Death In Epilepsy |
3.0% |
| Weight Increased |
3.0% |
| Grand Mal Convulsion |
2.5% |
| Product Quality Issue |
2.5% |
| Tremor |
2.5% |
| Drug Ineffective |
2.2% |
| Status Epilepticus |
2.2% |
| Stevens-johnson Syndrome |
2.2% |
| Headache |
2.0% |
| Dizziness |
1.7% |
| Drug Reaction With Eosinophilia And Systemic Symptoms |
1.7% |
|
| Secondary |
| Epilepsy |
29.9% |
| Product Used For Unknown Indication |
25.4% |
| Drug Use For Unknown Indication |
11.2% |
| Convulsion |
7.2% |
| Partial Seizures |
4.4% |
| Hypertension |
2.2% |
| Psychotic Disorder |
2.0% |
| Trigeminal Neuralgia |
2.0% |
| Completed Suicide |
1.9% |
| Mental Disorder |
1.9% |
| Depression |
1.5% |
| Foetal Exposure During Pregnancy |
1.5% |
| Bipolar Disorder |
1.4% |
| Status Epilepticus |
1.3% |
| Complex Partial Seizures |
1.1% |
| Anxiety |
1.0% |
| Ill-defined Disorder |
1.0% |
| Suicide Attempt |
1.0% |
| Intentional Overdose |
1.0% |
| Mania |
1.0% |
|
| Completed Suicide |
11.2% |
| Vomiting |
9.9% |
| Hyponatraemia |
9.6% |
| Rash |
6.6% |
| Convulsion |
5.8% |
| Drug Ineffective |
5.8% |
| Respiratory Arrest |
5.8% |
| Toxicity To Various Agents |
5.8% |
| Grand Mal Convulsion |
4.7% |
| Drug Interaction |
4.4% |
| Stevens-johnson Syndrome |
4.4% |
| Diplopia |
3.3% |
| Somnolence |
3.3% |
| Weight Increased |
3.3% |
| Death |
3.0% |
| Tremor |
3.0% |
| Cardio-respiratory Arrest |
2.7% |
| Poisoning |
2.7% |
| Cardiac Arrest |
2.5% |
| Drug Exposure During Pregnancy |
2.5% |
|
| Concomitant |
| Epilepsy |
22.6% |
| Product Used For Unknown Indication |
19.2% |
| Drug Use For Unknown Indication |
8.9% |
| Convulsion |
6.8% |
| Bipolar Disorder |
6.2% |
| Depression |
4.4% |
| Multiple Sclerosis |
4.3% |
| Hypertension |
3.7% |
| Pain |
3.4% |
| Partial Seizures |
2.9% |
| Rheumatoid Arthritis |
2.7% |
| Anxiety |
2.3% |
| Insomnia |
2.1% |
| Asthma |
1.9% |
| Blood Cholesterol Increased |
1.6% |
| Schizoaffective Disorder |
1.6% |
| Grand Mal Convulsion |
1.5% |
| Complex Partial Seizures |
1.4% |
| Schizophrenia |
1.4% |
| Osteoarthritis |
1.2% |
|
| Weight Increased |
10.5% |
| Vomiting |
9.4% |
| Convulsion |
7.7% |
| Drug Ineffective |
7.1% |
| Weight Decreased |
7.1% |
| Death |
6.0% |
| Granulocytopenia |
4.8% |
| Pregnancy |
4.8% |
| Somnolence |
4.8% |
| Psychotic Disorder |
4.5% |
| Nausea |
4.3% |
| Status Epilepticus |
3.7% |
| Depression |
3.4% |
| Grand Mal Convulsion |
3.4% |
| Hyponatraemia |
3.4% |
| Pain |
3.1% |
| Pyrexia |
3.1% |
| Rash |
3.1% |
| Epilepsy |
2.8% |
| Spinal Osteoarthritis |
2.8% |
|
| Interacting |
| Epilepsy |
27.4% |
| Convulsion |
14.5% |
| Drug Use For Unknown Indication |
13.1% |
| Post-traumatic Epilepsy |
8.7% |
| Respiratory Tract Infection |
7.1% |
| Prolactinoma |
6.0% |
| Product Used For Unknown Indication |
4.8% |
| Bipolar I Disorder |
2.9% |
| Hypertension |
2.7% |
| Vulvovaginal Mycotic Infection |
2.5% |
| Pain |
1.9% |
| Anxiety |
1.7% |
| Bipolar Disorder |
1.5% |
| Ill-defined Disorder |
1.2% |
| Neuralgia |
1.0% |
| Grand Mal Convulsion |
0.8% |
| Convulsion Prophylaxis |
0.6% |
| Mania |
0.6% |
| Maternal Exposure Timing Unspecified |
0.6% |
| Anticoagulant Therapy |
0.4% |
|
| Drug Interaction |
26.3% |
| Diplopia |
14.0% |
| Vomiting |
10.5% |
| Anticonvulsant Drug Level Decreased |
4.4% |
| Drug Toxicity |
4.4% |
| Neurotoxicity |
4.4% |
| Therapeutic Agent Toxicity |
4.4% |
| Ataxia |
3.5% |
| Galactorrhoea |
3.5% |
| Menstrual Disorder |
3.5% |
| Convulsion |
2.6% |
| Diarrhoea |
2.6% |
| Fall |
2.6% |
| Hyponatraemia |
2.6% |
| Abnormal Behaviour |
1.8% |
| International Normalised Ratio Decreased |
1.8% |
| Leukopenia |
1.8% |
| Mucosal Dryness |
1.8% |
| Orthostatic Hypotension |
1.8% |
| Psychomotor Hyperactivity |
1.8% |
|
